Transcenta of China Raises $105 Million to Develop Antibody Drugs

China 's Transcenta Holding completed a $105 million funding round to support its global antibody drug development operations as it advances toward commercial stage. The company's lead asset is TST001, a CLDN18.2 targeting antibody that has started US and China clinical trials. The company has a discovery center in Suzhou and a manufacturing facility in Hangzhou , plus clinical offices in China and the US . In January, Transcenta completed a $100 million Series B+ financing to develop its portfolio, which includes 10 innovative molecules in oncology, bone disorders and nephrology. More details.... Share this with colleagues: // //